Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 44

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 44
---
31, 2025, and December
31, 2024, respectively. We will require substantial future capital in order to continue operating our business, conduct research and development
and regulatory clearance and approval activities necessary to bring our products to market, and to establish effective marketing and sales
capabilities. Our existing capital resources are not sufficient to enable us to fund the completion of the development and commercialization
of all our product candidates.

To date, our operations have been
principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from
product sales. It is anticipated that we will continue to generate operating losses and use cash in operations. Our continuation as
a going concern is dependent upon our ability to increase sales, decrease expenses and raise additional funding. Whether and when we
can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.

We are actively generating
additional scientific and clinical data to have it published in leading industry publications. We believe the publication of such
data would help sales efforts as we approach new prospects. We are also making additional changes to our sales
strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion
applications. For instance, results from an independent study demonstrated the potential anti-viral properties of our silicon
nitride.

On February 20, 2025, we entered
into a private placement transaction pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with certain
institutional and accredited investors for aggregate gross proceeds of $5.0 million, before deducting fees to the placement agent
and other expenses payable by us in connection with the Private Placement. We intend to use the net proceeds from
the Private Placement for general corporate purposes and working capital. H.C. Wainwright & Co. (“Wainwright”),
acted as the exclusive placement agent for the Private Placement, which closed on February 25, 2025. As part of the Private
Placement, we issued (i) 1,171,189 shares of our common stock, par value $0.01 per share (“Common
Stock”), (ii) pre-funded warrants to purchase 278,098 shares of Common Stock (the “Pre-Funded Warrants”) with an
exercise price of $0.0001 per share, and (iii) warrants to purchase 1,449,287 shares of Common Stock (the “Common
Warrants,” together with the Pre